Lund, Sweden — 14 February 2019 — Camurus (NASDAQ STO: CAMX) today announces that Fredrik Tiberg, President and CEO, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Healthcare Conference in Boston, Massachusetts. The presentation will take place on Monday 11 March 2019 at 4:10 pm Eastern Standard Time and can be accessed via a live webcast at Camurus website www.camurus.com. An archived version of the webcast will be available for 30 days after the event.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
This information was submitted for publication at 8.00 am CET on 14 February 2019.